Skip to main content

Table 3 Effects of treatment on LV dimensions and function

From: Potential advantages of cell administration on the inflammatory response compared to standard ACE inhibitor treatment in experimental myocardial infarction

-1 days

0 days #

7 days

14 days

 

UT

ACE-I

BMMNCs

UT

ACE-I

BMMNCs

UT

ACE-I

BMMNCs

UT

ACE-I

BMMNCs

LAd mm

2.3 ± 0.2

2.2 ± 0.2

2.2 ± 0.3

3.2 ± 0.3

2.7 ± 0.4*

3.1 ± 0.4

3.4 ± 0.2

2.7 ± 0.4**

3.1 ± 0.3

3.5 ± 0.3

2.7 ± 0.4*

2.6 ± 0.6*

LVEDd mm

5.0 ± 0.5

5.1 ± 0.1

5.1 ± 0.2

5.5 ± 0.5

5.2 ± 0.2

5.4 ± 0.3

5.5 ± 0.7

5.3 ± 0.2

5.4 ± 0.2

5.6 ± 0.7

5.4 ± 0.2

5.3 ± 0.3

E/A

3.9 ± 0.1

3.9 ± 0.1

3.8 ± 0.1

3.7 ± 0.5

3.6 ± 0.4

3.3 ± 0.3

3.5 ± 0.4

3.6 ± 0.5

3.0 ± 0.3

3.4 ± 0.5

3.4 ± 0.6

2.6 ± 0.4

FS %

50.1 ± 1.0

50.2 ± 2.5

49.9 ± 1.7

39.9 ± 4.8

47.4 ± 3.5**

42.2 ± 3.8

38.0 ± 3.6

46.8 ± 3.6**

39.6 ± 3.6§

37.4 ± 3.4

45.3 ± 3.6**

43.5 ± 3.9*

EF %

80.0 ± 0.8

81.9 ± 3.4

81.8 ± 1.3

71.8 ± 5.5

80.1 ± 3.1**

76.4 ± 4.6

71.7 ± 5.2

81.3 ± 3.6**

77.8 ± 4.4

72.2 ± 4.8

81.1 ± 3.6**

77.8 ± 4.1

  1. LAd = Left Atrial Diameter; LVEDd = Left Ventricular End Diastolic Diameter; E/A = ratio between the velocities of E and A waves of the mitral diastolic flow; FS = Fractional Shortening.
  2. # data on day 0 refer to echocardiograms performed 6–24 hours from injury.
  3. *p = 0.05 vs UT ; **p = 0.01 vs UT; §p = 0.01 vs ACE-I